Reports
Global Cancer Screening Market: By Cancer Type; By Technique: Imaging Techniques, Endoscopy, Biopsy and Cytology Tests; Genomic and Molecular tests; Others; By Stage: TNM Stages, Others; By Gender; Regional Analysis; Historical Market and Forecast (2018-2028); Market Dynamics; Competitive Landscape; Industry Events and Developments
Global Cancer Screening Market Outlook
The global cancer screening market is expected to grow in the forecast period of 2023-2028 at a CAGR of 9%.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Increasing Focus on Early Detection and Prevention of Cancer Aiding the Growth of Cancer Screening Industry
The cancer screening industry is being aided by the surging cancer cases across the world. The development of superior imaging to identify the cancerous tissues of different cancer types is also propelling the market growth. As cancer is one of the leading causes of death worldwide, the demand for early detection and cure of the chronic disease is rising. Screenings are increasingly used to detect cancers and to reduce the death rates from the illness. The Asia Pacific region is expected to witness significant growth due to the rising cancer cases attributed to unhealthy lifestyles and the rising consumption of tobaccos and other carcinogenic products. Moreover, the increasing penetration of technological advancements and the improving healthcare infrastructure, along with the rising awareness of various chronic diseases in the emerging economies, such as India, China, Indonesia, and Brazil, among others, are lubricating the market growth.
Geographically, North America holds a significant share of the market due to the surging cancer cases in the country as well as increasing research and development (R&D) to diagnose and treat cancer effectively. Moreover, the advancement of biotechnology and the presence of global players in the region are further fuelling the market growth. The Control of Centre of Diseases and Prevention (CDC) of the United States offers various programs, such as National Breast and Cervical Early Cancer Detection Program (NBCCEDP), through which cost-effective screening is offered to the patients. Such initiatives are lubricating the industry growth.
Cancer Screening: Market Segmentation
Cancer screening is a test that can aid in detecting cancer at an early stage before symptoms appear. It decreases the chance of the cancerous cells to grow abnormally and reduces the mortality rates of the person. Each type of cancer has its screening test, which can aid in detecting cancer in its early stages.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Based on the cancer types, the industry is divided into:
- Lung Cancer
- Blood Cancer
- Bone Cancer
- Gall Bladder Cancer
- Testicular Cancer
- Thyroid Cancer
- Breast Cancer
- Others
The major techniques of cancer screening are:
- Imaging Techniques
- CT Scan
- MRI
- Others
- Endoscopy
- Colonoscopy
- Sigmoidoscopy
- Others
- Biopsy and Cytology Tests
- Needle Biopsy
- CT-Guided Biopsy
- Others
- Genomic and Molecular tests
- Next Generation Sequencing (NGS)
- RT- PCR
- Others
The market can be broadly categorised on the basis of stage by:
- TNM Stages
- Stages 0, 1, 2, 3, 4
- Prognostic Factors
- Others
On the basis of gender, the market is segmented into:
- Men
- Women
The EMR report looks into the regional markets of cancer screening like North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Technological Advancements to Aid the Growth of the Cancer Screening Industry
Screening can detect cancer at an early stage, due to which the treatment can be started in the early stages, which can reduce the risk of death. The rising cases of death due to cancer is driving the market growth. Increasing research and development (R&D) to create effective treatments and early diagnosis of cancer is further propelling the market growth. Innovative technologies such as positron emission mammography, spectroscopy-enhanced colonoscopy, and hyperpolarisation MRI, among others, are increasing the efficiency of screening, consequently aiding the industry growth. Moreover, further research and innovations in the field of leukaemia and ovarian cancer, which are currently difficult to screen, are further expected to propel the industry growth in the forecast period.
The use of artificial intelligence (AI) to improve the accuracy, the speed of diagnosis, and reduce health disparity in a low-resource setting is driving the market growth. As artificial intelligence can aid clinical decision making, identify specific gene mutations, and improve MRI guided biopsy, they are used in research by various organisations, such as National Cancer Institute, which is providing further impetus to the market growth. Moreover, the use of advanced technology such as real-time data analysis, computation and digital pathology, and molecular diagnostics to enable pattern recognition in population data to predict treatment response, survival, and the likelihood of recurrence are further anticipated to aid the market growth.
Key Industry Players in the Global Cancer Screening Market
The report presents a detailed analysis of the following key players in the global cancer screening market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- DiaSorin S.p.A.
- Epigenomics AG
- Techlab, Inc.
- Positive Biosciences Limited
- MedGenome Labs Ltd
- 20/20 GeneSystems
- Others
The comprehensive report looks into the macro and micro aspects of the industry. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2018-2022 |
| Forecast Period | 2023-2028 |
| Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Type, Technique, Stage, Gender, Region |
| Breakup by Type | Lung Cancer, Blood Cancer, Bone Cancer, Gall Bladder Cancer, Testicular Cancer, Thyroid Cancer, Breast Cancer, Others |
| Breakup by Technique | Imaging Techniques, Endoscopy, Biopsy and Cytology Tests, Genomic and Molecular tests |
| Breakup by Stage | TNM Stages, Stages 0, 1, 2, 3, 4, Prognostic Factors, Others |
| Breakup by Gender | Men, Women |
| Breakup by Regions | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Market Dynamics | SWOT, Porter's Five Forces, Key Indicators for Price and Demand |
| Competitive Landscape | Market Structure, Company Profiles-Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
| Companies Covered | DiaSorin S.p.A., Epigenomics AG, Techlab, Inc., Positive Biosciences Limited, MedGenome Labs Ltd, 20/20 GeneSystems, Others |
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Opportunities and Challenges in the Market
8 Global Cancer Screening Market Analysis
8.1 Key Industry Highlights
8.2 Global Cancer Screening Historical Market (2018-2022)
8.3 Global Cancer Screening Market Forecast (2023-2028)
8.4 Global Cancer Screening Market by Cancer Type
8.4.1 Lung Cancer
8.4.1.1 Historical Trend (2018-2022)
8.4.1.2 Forecast Trend (2023-2028)
8.4.2 Blood Cancer
8.4.2.1 Historical Trend (2018-2022)
8.4.2.2 Forecast Trend (2023-2028)
8.4.3 Bone Cancer
8.4.3.1 Historical Trend (2018-2022)
8.4.3.2 Forecast Trend (2023-2028)
8.4.4 Gall Bladder Cancer
8.4.4.1 Historical Trend (2018-2022)
8.4.4.2 Forecast Trend (2023-2028)
8.4.5 Testicular Cancer
8.4.5.1 Historical Trend (2018-2022)
8.4.5.2 Forecast Trend (2023-2028)
8.4.6 Thyroid Cancer
8.4.6.1 Historical Trend (2018-2022)
8.4.6.2 Forecast Trend (2023-2028)
8.4.7 Breast Cancer
8.4.7.1 Historical Trend (2018-2022)
8.4.7.2 Forecast Trend (2023-2028)
8.4.8 Others
8.5 Global Cancer Screening Market by Technique
8.5.1 Imaging Techniques
8.5.1.1 Historical Trend (2018-2022)
8.5.1.2 Forecast Trend (2023-2028)
8.5.1.3 Breakup by Type
8.5.1.3.1 CT Scan
8.5.1.3.1.1 Historical Trend (2018-2022)
8.5.1.3.1.2 Forecast Trend (2023-2028)
8.5.1.3.2 MRI
8.5.1.3.2.1 Historical Trend (2018-2022)
8.5.1.3.2.2 Forecast Trend (2023-2028)
8.5.1.3.3 Others
8.5.2 Endoscopy
8.5.2.1 Historical Trend (2018-2022)
8.5.2.2 Forecast Trend (2023-2028)
8.5.2.3 Breakup by Type
8.5.2.3.1 Colonoscopy
8.5.2.3.1.1 Historical Trend (2018-2022)
8.5.2.3.1.2 Forecast Trend (2023-2028)
8.5.2.3.2 Sigmoidoscopy
8.5.2.3.2.1 Historical Trend (2018-2022)
8.5.2.3.2.2 Forecast Trend (2023-2028)
8.5.2.3.3 Others
8.5.3 Biopsy and Cytology Tests
8.5.3.1 Historical Trend (2018-2022)
8.5.3.2 Forecast Trend (2023-2028)
8.5.3.3 Breakup by Type
8.5.3.3.1 Needle Biopsy
8.5.3.3.1.1 Historical Trend (2018-2022)
8.5.3.3.1.2 Forecast Trend (2023-2028)
8.5.3.3.2 CT - Guided Biopsy
8.5.3.3.2.1 Historical Trend (2018-2022)
8.5.3.3.2.2 Forecast Trend (2023-2028)
8.5.3.3.3 Others
8.5.4 Genomic and Molecular tests
8.5.4.1 Historical Trend (2018-2022)
8.5.4.2 Forecast Trend (2023-2028)
8.5.4.3 Breakup by Type
8.5.4.3.1 Next Generation Sequencing (NGS)
8.5.4.3.1.1 Historical Trend (2018-2022)
8.5.4.3.1.2 Forecast Trend (2023-2028)
8.5.4.3.2 RT- PCR
8.5.4.3.2.1 Historical Trend (2018-2022)
8.5.4.3.2.2 Forecast Trend (2023-2028)
8.5.4.3.3 Others
8.6 Global Cancer Screening Market by Stage
8.6.1 TNM Stages
8.6.1.1 Historical Trend (2018-2022)
8.6.1.2 Forecast Trend (2023-2028)
8.6.2 Stages 0, 1, 2, 3, 4
8.6.2.1 Historical Trend (2018-2022)
8.6.2.2 Forecast Trend (2023-2028)
8.6.3 Prognostic Factors
8.6.3.1 Historical Trend (2018-2022)
8.6.3.2 Forecast Trend (2023-2028)
8.6.4 Others
8.7 Global Cancer Screening Market by Gender
8.7.1 Men
8.7.1.1 Historical Trend (2018-2022)
8.7.1.2 Forecast Trend (2023-2028)
8.7.2 Women
8.7.2.1 Historical Trend (2018-2022)
8.7.2.2 Forecast Trend (2023-2028)
8.8 Global Cancer Screening Market by Region
8.8.1 North America
8.8.1.1 Historical Trend (2018-2022)
8.8.1.2 Forecast Trend (2023-2028)
8.8.2 Europe
8.8.2.1 Historical Trend (2018-2022)
8.8.2.2 Forecast Trend (2023-2028)
8.8.3 Asia Pacific
8.8.3.1 Historical Trend (2018-2022)
8.8.3.2 Forecast Trend (2023-2028)
8.8.4 Latin America
8.8.4.1 Historical Trend (2018-2022)
8.8.4.2 Forecast Trend (2023-2028)
8.8.5 Middle East and Africa
8.8.5.1 Historical Trend (2018-2022)
8.8.5.2 Forecast Trend (2023-2028)
9 North America Cancer Screening Market Analysis
9.1 United States of America
9.1.1 Historical Trend (2018-2022)
9.1.2 Forecast Trend (2023-2028)
9.2 Canada
9.2.1 Historical Trend (2018-2022)
9.2.2 Forecast Trend (2023-2028)
10 Europe Cancer Screening Market Analysis
10.1 United Kingdom
10.1.1 Historical Trend (2018-2022)
10.1.2 Forecast Trend (2023-2028)
10.2 Germany
10.2.1 Historical Trend (2018-2022)
10.2.2 Forecast Trend (2023-2028)
10.3 France
10.3.1 Historical Trend (2018-2022)
10.3.2 Forecast Trend (2023-2028)
10.4 Italy
10.4.1 Historical Trend (2018-2022)
10.4.2 Forecast Trend (2023-2028)
10.5 Others
11 Asia Pacific Cancer Screening Market Analysis
11.1 China
11.1.1 Historical Trend (2018-2022)
11.1.2 Forecast Trend (2023-2028)
11.2 Japan
11.2.1 Historical Trend (2018-2022)
11.2.2 Forecast Trend (2023-2028)
11.3 India
11.3.1 Historical Trend (2018-2022)
11.3.2 Forecast Trend (2023-2028)
11.4 ASEAN
11.4.1 Historical Trend (2018-2022)
11.4.2 Forecast Trend (2023-2028)
11.5 Australia
11.5.1 Historical Trend (2018-2022)
11.5.2 Forecast Trend (2023-2028)
11.6 Others
12 Latin America Cancer Screening Market Analysis
12.1 Brazil
12.1.1 Historical Trend (2018-2022)
12.1.2 Forecast Trend (2023-2028)
12.2 Argentina
12.2.1 Historical Trend (2018-2022)
12.2.2 Forecast Trend (2023-2028)
12.3 Mexico
12.3.1 Historical Trend (2018-2022)
12.3.2 Forecast Trend (2023-2028)
12.4 Others
13 Middle East and Africa Cancer Screening Market Analysis
13.1 Saudi Arabia
13.1.1 Historical Trend (2018-2022)
13.1.2 Forecast Trend (2023-2028)
13.2 United Arab Emirates
13.2.1 Historical Trend (2018-2022)
13.2.2 Forecast Trend (2023-2028)
13.3 Nigeria
13.3.1 Historical Trend (2018-2022)
13.3.2 Forecast Trend (2023-2028)
13.4 South Africa
13.4.1 Historical Trend (2018-2022)
13.4.2 Forecast Trend (2023-2028)
13.5 Others
14 Market Dynamics
14.1 SWOT Analysis
14.1.1 Strengths
14.1.2 Weaknesses
14.1.3 Opportunities
14.1.4 Threats
14.2 Porter’s Five Forces Analysis
14.2.1 Supplier’s Power
14.2.2 Buyer’s Power
14.2.3 Threat of New Entrants
14.2.4 Degree of Rivalry
14.2.5 Threat of Substitutes
14.3 Key Indicators for Demand
14.4 Key Indicators for Price
15 Value Chain Analysis
16 Competitive Landscape
16.1 Market Structure
16.2 Company Profiles
16.2.1 DiaSorin S.p.A.
16.2.1.1 Company Overview
16.2.1.2 Product Portfolio
16.2.1.3 Demographic Reach and Achievements
16.2.1.4 Certifications
16.2.2 Epigenomics AG
16.2.2.1 Company Overview
16.2.2.2 Product Portfolio
16.2.2.3 Demographic Reach and Achievements
16.2.2.4 Certifications
16.2.3 Techlab, Inc.
16.2.3.1 Company Overview
16.2.3.2 Product Portfolio
16.2.3.3 Demographic Reach and Achievements
16.2.3.4 Certifications
16.2.4 Positive Biosciences Limited
16.2.4.1 Company Overview
16.2.4.2 Product Portfolio
16.2.4.3 Demographic Reach and Achievements
16.2.4.4 Certifications
16.2.5 MedGenome Labs Ltd
16.2.5.1 Company Overview
16.2.5.2 Product Portfolio
16.2.5.3 Demographic Reach and Achievements
16.2.5.4 Certifications
16.2.6 20/20 GeneSystems
16.2.6.1 Company Overview
16.2.6.2 Product Portfolio
16.2.6.3 Demographic Reach and Achievements
16.2.6.4 Certifications
16.2.7 Others
17 Key Trends and Developments in the Market
List of Key Figures and Tables
1. Global Cancer Screening Market: Key Industry Highlights, 2018 and 2028
2. Global Cancer Screening Historical Market: Breakup by Type (USD Billion), 2018-2022
3. Global Cancer Screening Market Forecast: Breakup by Type (USD Billion), 2023-2028
4. Global Cancer Screening Historical Market: Breakup by Technique (USD Billion), 2018-2022
5. Global Cancer Screening Market Forecast: Breakup by Technique (USD Billion), 2023-2028
6. Global Cancer Screening Historical Market: Breakup by Stage (USD Billion), 2018-2022
7. Global Cancer Screening Market Forecast: Breakup by Stage (USD Billion), 2023-2028
8. Global Cancer Screening Historical Market: Breakup by Gender (USD Billion), 2018-2022
9. Global Cancer Screening Market Forecast: Breakup by Gender (USD Billion), 2023-2028
10. Global Cancer Screening Historical Market: Breakup by Region (USD Billion), 2018-2022
11. Global Cancer Screening Market Forecast: Breakup by Region (USD Billion), 2023-2028
12. North America Cancer Screening Historical Market: Breakup by Country (USD Billion), 2018-2022
13. North America Cancer Screening Market Forecast: Breakup by Country (USD Billion), 2023-2028
14. Europe Cancer Screening Historical Market: Breakup by Country (USD Billion), 2018-2022
15. Europe Cancer Screening Market Forecast: Breakup by Country (USD Billion), 2023-2028
16. Asia Pacific Cancer Screening Historical Market: Breakup by Country (USD Billion), 2018-2022
17. Asia Pacific Cancer Screening Market Forecast: Breakup by Country (USD Billion), 2023-2028
18. Latin America Cancer Screening Historical Market: Breakup by Country (USD Billion), 2018-2022
19. Latin America Cancer Screening Market Forecast: Breakup by Country (USD Billion), 2023-2028
20. Middle East and Africa Cancer Screening Historical Market: Breakup by Country (USD Billion), 2018-2022
21. Middle East and Africa Cancer Screening Market Forecast: Breakup by Country (USD Billion), 2023-2028
22. Global Cancer Screening Market Structure
Key Questions Answered in the Report
The cancer screening market is projected to grow at a CAGR of 9% between 2023 and 2028.
The industry is being aided by the surge of cancer cases worldwide and the increasing efforts and favourable government initiatives to prevent cancer by diagnosing them at early stages.
The industry is driven by the technological advancements, increasing research and development (R&D) to prevent and detect cancer, and the use of advanced technology such as artificial intelligence (AI) and real-time data analytics to detect cancer efficiently.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific, with North America accounting for the largest share in the market.
The major cancer types of cancer screening in the industry are lung cancer, blood cancer, bone cancer, gall bladder cancer, testicular cancer, thyroid cancer, and breast cancer, among others.
The significant techniques in the market are imaging techniques, endoscopy, biopsy and cytology tests, and genomic and molecular tests.
The leading stages of cancer screening in the market are TNM stages, stages 0, 1, 2, 3, 4, and prognostic factors, among others.
The dominant genders in the industry are men and women.
The major players in the industry are DiaSorin S.p.A., Epigenomics AG, Techlab, Inc., Positive Biosciences Limited, MedGenome Labs Ltd, and 20/20 GeneSystems, among others.
Analyst Review
The global cancer screening market is driven by the surging cancer rates around the globe. Aided by the growing technological advancements, the market is expected to witness a further growth in the forecast period of 2023-2028, growing at a CAGR of 9%.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on its cancer types, the industry can be segmented into lung cancer, blood cancer, bone cancer, gall bladder cancer, testicular cancer, thyroid cancer, and breast cancer, among others. On the basis of technique, the industry is divided into imaging techniques, endoscopy, biopsy and cytology tests, and genomic and molecular tests. The major stages in the industry are TNM stages, stages 0, 1, 2, 3, 4, and prognostic factors, among others. Based on the gender, the industry is categorised into men and women. The major regional markets for cancer screening are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa, with North America accounting for the largest share of the market. The key players in the above market include DiaSorin S.p.A., Epigenomics AG, Techlab, Inc., Positive Biosciences Limited, MedGenome Labs Ltd, and 20/20 GeneSystems, among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$1699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$2799-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$3999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER